InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

- Current share price for SPL : $0.725

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$346 Starpharma signs DEP Research Agreement with US Biopharma Co 7 Dec 2021 9:08AM $1.145 $0.725 fallen by 36.68%
$346 Change in Director's Interest Notice - J Fairley 3 Dec 2021 2:30PM $1.190 $0.725 fallen by 39.08%
$346 Notification regarding unquoted securities - SPL 3 Dec 2021 2:26PM $1.190 $0.725 fallen by 39.08%
$346 VIRALEZE distribution agreement and launch in Vietnam 3 Dec 2021 9:34AM $1.170 $0.725 fallen by 38.03%
$346 VIRALEZE registered in Vietnam with launch this week 1 Dec 2021 9:28AM $1.085 $0.725 fallen by 33.18%
$346 AGM Results 30 Nov 2021 2:32PM $1.095 $0.725 fallen by 33.79%
$346 AGM Chairman address and CEO presentation 30 Nov 2021 10:07AM $1.045 $0.725 fallen by 30.62%
$346 Positive DEP phase 2 interim results in prostate cancer 25 Nov 2021 11:03AM $1.095 $0.725 fallen by 33.79%
$346 Jobkeeper s323DB(1) notice 11 Nov 2021 2:19PM $1.055 $0.725 fallen by 31.28%
$346 Starpharma to present at Bell Potter Healthcare Conference 9 Nov 2021 1:20PM $1.088 $0.725 fallen by 33.33%
$346 Application for quotation of securities - SPL 1 Nov 2021 2:35PM $1.070 $0.725 fallen by 32.24%
$346 Notice of Annual General Meeting/Proxy Form 29 Oct 2021 2:05PM $1.090 $0.725 fallen by 33.49%
$346 Quarterly Cashflow and Activities Report 29 Oct 2021 9:57AM $1.070 $0.725 fallen by 32.24%
$346 Starpharma to present DEP at US Drug Delivery Conference 28 Oct 2021 9:54AM $1.050 $0.725 fallen by 30.95%
$346 VIRALEZE distribution and supply to Vietnam 26 Oct 2021 9:57AM $1.080 $0.725 fallen by 32.87%
$346 Notification regarding unquoted securities - SPL 25 Oct 2021 3:19PM $1.080 $0.725 fallen by 32.87%
$346 VIRALEZE ADMENTA agreement - supplementary information 12 Oct 2021 11:33AM $1.175 $0.725 fallen by 38.30%
$346 VIRALEZE launch in ADMENTA Italia Group pharmacies in Italy 8 Oct 2021 9:25AM $1.195 $0.725 fallen by 39.33%
$346 Change in Director's Interest Notice - J Fairley 1 Oct 2021 2:31PM $1.300 $0.725 fallen by 44.23%
$346 Notification of cessation of securities - SPL 1 Oct 2021 2:24PM $1.305 $0.725 fallen by 44.44%
$346 2021 Annual General Meeting 1 Oct 2021 2:18PM $1.300 $0.725 fallen by 44.23%
$346 US patent issued for DEP cabazitaxel nanoparticle 15 Sep 2021 9:17AM $1.310 $0.725 fallen by 44.66%
$346 Application for quotation of securities - SPL 13 Sep 2021 4:41PM $1.300 $0.725 fallen by 44.23%
$346 Change in Director's Interest Notice - Z Peach 31 Aug 2021 4:14PM $1.205 $0.725 fallen by 39.83%
$346 Change in Director's Interest Notice - J Fairley 30 Aug 2021 10:44AM $1.145 $0.725 fallen by 36.68%

276 - 300 of 875 results

Page 12 of 35

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.